Aakaar Medical Technologies Limited

Aakaar Medical Technologies Limited

NNSE:AAKAAR
66.00
INR
+0.40
(+0.61%)
Aakaar Medical Technologies Limited
NSE:AAKAAR
(National Stock Exchange of India)

Recent

price

66.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Aakaar Medical Technologies Limited is an India-based medical technology company that specializes in the development, manufacturing, import, marketing, and distribution of medical aesthetic devices, clinical dermatology formulations, and specialized skincare products. The company operates primarily through a business-to-business model, supplying dermatologists, plastic surgeons, trichologists, cosmetic clinics, and aesthetic healthcare practitioners across India. Its core product portfolio encompasses advanced energy-based and diagnostic aesthetic equipment; professional and home-care cosmeceuticals; hair restoration solutions; injectable contouring products; and clinical dermatology therapeutics. The company's aesthetic device offerings include laser platforms such as the Magnus BB Thulium Laser, VeraTouch CO2 Laser, Magnus Pico, and Maxwave; diagnostic and skin imaging systems including the DermLite DL5 dermatoscope and FotoFinder SKEEN; and therapeutic systems such as Platina Ice+, Regenera Activa AMT, TUBELiTE Synergy+, and FeMIChair. Its formulation and consumable portfolio features chemical peels, post-procedure recovery treatments, medifacials, cleansers, serums, and sunscreens marketed under proprietary brand names including TUBELiTE, Balback, Lytec, Etrelume, Swyada, Exoluxe, DRS1512, and Eoluxe; injectable aesthetic threads under the Aqulift brand; and clinical dermatology therapies under the Tinefcon brand. In recent corporate developments, the company transitioned from a private entity to a public limited company in November 2024, changing its name from Aakaar Medical Technologies Private Limited to Aakaar Medical Technologies Limited, and completed an initial public offering on the NSE Emerge platform in June 2025, raising 27.00 crore INR in fresh capital. In addition, the company has expanded its domestic brand portfolio with the rollouts of the Etrelume, Swyada, and Exoluxe lines, deepened strategic international distribution alliances with global aesthetic manufacturers including Medytox Inc., Innoaesthetics, Theraderm, and Croma-Pharma, and advanced plans to establish a dedicated aesthetic medical device manufacturing facility in Pune to scale domestic production alongside its nationwide sales and technical service network. Founded in 2013, Aakaar Medical Technologies Limited is headquartered in Mumbai, Maharashtra, India.